Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

2.

Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries.

Pujades-Rodríguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A; AIDS Working Group of MSF.

JAMA. 2010 Jul 21;304(3):303-12. doi: 10.1001/jama.2010.980.

PMID:
20639564
[PubMed - indexed for MEDLINE]
3.

Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.

El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, Karstaedt A, Charalambous S, Petzold M, Katzenstein D, Morris L.

AIDS. 2010 Jul 17;24(11):1679-87. doi: 10.1097/QAD.0b013e32833a097b.

PMID:
20453629
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Protease inhibitor resistance in South African children with virologic failure.

van Zyl GU, van der Merwe L, Claassen M, Cotton MF, Rabie H, Prozesky HW, Preiser W.

Pediatr Infect Dis J. 2009 Dec;28(12):1125-7. doi: 10.1097/INF.0b013e3181af829d.

PMID:
19779394
[PubMed - indexed for MEDLINE]
5.

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

Arribas JR, Delgado R, Arranz A, Muñoz R, Portilla J, Pasquau J, Pérez-Elias MJ, Iribarren JA, Rubio R, Ocampo A, Sánchez-Conde M, Knobel H, Arazo P, Sanz J, López-Aldeguer J, Montes ML, Pulido F; OK04 Study Group.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):147-52. doi: 10.1097/QAI.0b013e3181a56de5.

PMID:
19349870
[PubMed - indexed for MEDLINE]
6.

A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.

Gathe J, da Silva BA, Cohen DE, Loutfy MR, Podzamczer D, Rubio R, Gibbs S, Marsh T, Naylor C, Fredrick L, Bernstein B.

J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):474-81. doi: 10.1097/QAI.0b013e31819c2937.

PMID:
19225400
[PubMed - indexed for MEDLINE]
7.

Protease inhibitor levels in hair strongly predict virologic response to treatment.

Gandhi M, Ameli N, Bacchetti P, Gange SJ, Anastos K, Levine A, Hyman CL, Cohen M, Young M, Huang Y, Greenblatt RM; Women's Interagency HIV Study (WIHS).

AIDS. 2009 Feb 20;23(4):471-8. doi: 10.1097/QAD.0b013e328325a4a9.

PMID:
19165084
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry.

Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin ET, Messenkoff N.

Rapid Commun Mass Spectrom. 2008 Nov;22(21):3401-9. doi: 10.1002/rcm.3750.

PMID:
18837069
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Class-sparing regimens for initial treatment of HIV-1 infection.

Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW; AIDS Clinical Trials Group Study A5142 Team.

N Engl J Med. 2008 May 15;358(20):2095-106. doi: 10.1056/NEJMoa074609.

PMID:
18480202
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.

van Zyl GU, Claassen M, Engelbrecht S, Laten JD, Cotton MF, Theron GB, Preiser W.

J Med Virol. 2008 Jun;80(6):942-6. doi: 10.1002/jmv.21157.

PMID:
18428139
[PubMed - indexed for MEDLINE]
11.

Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance.

Gardner EM, Sharma S, Peng G, Hullsiek KH, Burman WJ, Macarthur RD, Chesney M, Telzak EE, Friedland G, Mannheimer SB.

AIDS. 2008 Jan 2;22(1):75-82.

PMID:
18090394
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Practical and conceptual challenges in measuring antiretroviral adherence.

Berg KM, Arnsten JH.

J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S79-87. Review.

PMID:
17133207
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Tolerance of didanosine as enteric-coated capsules versus buffered tablets.

Barreiro P, Corbatón A, Núñez M, González-Lahoz J, Soriano V.

AIDS Patient Care STDS. 2004 Jun;18(6):329-31. No abstract available.

PMID:
15294082
[PubMed - indexed for MEDLINE]
15.

Paradoxes of adherence and drug resistance to HIV antiretroviral therapy.

Bangsberg DR, Moss AR, Deeks SG.

J Antimicrob Chemother. 2004 May;53(5):696-9. Epub 2004 Mar 24. Review.

PMID:
15044425
[PubMed - indexed for MEDLINE]
Free Article
16.

Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy.

Quiros-Roldan E, Airoldi M, Moretti F, Fausti C, Pan A, Casari S, Torti C, Castelli F, Carosi G.

J Clin Lab Anal. 2002;16(2):76-8.

PMID:
11948795
[PubMed - indexed for MEDLINE]
17.

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.

Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, Huraux JM, Katlama C, Calvez V.

J Med Virol. 2001 Nov;65(3):445-8.

PMID:
11596076
[PubMed - indexed for MEDLINE]
18.

Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection.

Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ.

J Virol. 2000 Jul;74(14):6262-8.

PMID:
10864635
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Comparative dispositions of ofloxacin in human head, axillary, and pubic hairs.

Kosuge K, Uematsu T, Araki SI, Matsuno H, Ohashi K, Nakashima M.

Antimicrob Agents Chemother. 1998 May;42(5):1298-302.

PMID:
9593174
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Experience with hair testing in the clinical biochemistry laboratory of Ca' Granda Niguarda Hospital, Milan, Italy.

Cassani M, Da Re N, Giuliani L, Sesana F.

Forensic Sci Int. 1997 Jan 17;84(1-3):17-24.

PMID:
9042706
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk